LON:N4P N4 Pharma (N4P) Share Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free N4P Stock Alerts GBX 0.80 -0.03 (-3.03%) (As of 03:54 PM ET) Add Compare Share Share Today's Range 0.80▼ 0.9050-Day Range 0.60▼ 0.8552-Week Range 0.60▼ 2.20Volume3.45 million shsAverage Volume1.28 million shsMarket Capitalization£2.15 millionP/E RatioN/ADividend Yield3.12%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsStock AnalysisChartCompetitors Get N4 Pharma alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About N4 Pharma Stock (LON:N4P)N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.Read More N4P Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart N4P Stock News HeadlinesApril 19, 2024 | lse.co.ukN4 Pharma sees potential in Nuvec delivery method for cancer treatmentJanuary 24, 2024 | lse.co.ukN4 Pharma Plc Share ChatApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.September 28, 2023 | marketwatch.comN4 Pharma Acquires Major Stake in Nanogenics Through Discounted Share Placing; Shares FallJuly 25, 2023 | marketwatch.comN4 Pharma Shares Rise After Further Nuvec Patent Granted in USApril 26, 2023 | marketwatch.comN4 Pharma Shares Rise on Development of Nuvec TestMarch 9, 2023 | marketwatch.comN4 Pharma's Pretax Loss Narrowed in 2022 on Lower R&D CostsFebruary 26, 2023 | seekingalpha.comMicrocap Timber Pharmaceuticals up 46% on orphan drug designation for skin disorder drugApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.January 18, 2023 | marketwatch.comN4 Pharma Shares Rise on Positive Nuvec Oral Application ResultsNovember 1, 2022 | marketwatch.comN4 Pharma Enhances Nuvec's Application Claims in Bid to Gain Patent ProtectionOctober 11, 2022 | finance.yahoo.comInstitutions profited after N4 Pharma Plc's (LON:N4P) market cap rose UK£2.9m last week butindividual investors profited the mostOctober 4, 2022 | marketwatch.comN4 Pharma Shares Rise on Successful Testing of Nuvec, Vaccine SystemSeptember 29, 2022 | marketwatch.comN4 Pharma Narrows 1H Loss by Controlling Expenditure; Shares RiseSeptember 3, 2022 | uk.investing.comFTSE South Africa Technical AnalysisAugust 13, 2022 | finance.yahoo.comN4 Pharma Plc (N4P.L)July 15, 2022 | marketwatch.comN4 Pharma Shares Rise on Further Nuvec ProgressJune 13, 2022 | marketwatch.comN4 Pharma Shares Rise on Positive Results for Nuvec Delivery SystemMarch 31, 2022 | finance.yahoo.comBeroni Group Announces Appointment of Dr. John Chiplin to Board of DirectorsJanuary 31, 2022 | marketwatch.comN4 Pharma Says Nuvec Granted Patents in U.S., ChinaJanuary 25, 2022 | marketwatch.comN4 Pharma to Work on Nuvec With Medicines Discovery Catapult Following Encouraging ResultsDecember 13, 2021 | marketwatch.comN4 Pharma to Focus Resources on Advancing Gene Therapy WorkAugust 30, 2021 | finance.yahoo.comWe Think N4 Pharma (LON:N4P) Can Afford To Drive Business GrowthAugust 24, 2021 | marketwatch.comN4 Pharma Says Nuvec Studies Are Progressing WellSee More Headlines Receive N4P Stock News and Ratings via Email Sign-up to receive the latest news and ratings for N4 Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/17/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:N4P CUSIPN/A CIKN/A Webwww.n4pharma.com Phone+44-1332-690061FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.34% Return on Assets-43.80% Debt Debt-to-Equity Ratio1.62 Current Ratio27.88 Quick Ratio7.28 Sales & Book Value Annual Sales£23,524.00 Price / Sales91.41 Cash FlowGBX 0.36 per share Price / Cash Flow2.25 Book ValueGBX 1 per share Price / Book0.80Miscellaneous Outstanding Shares268,780,000Free FloatN/AMarket Cap£2.15 million OptionableNot Optionable Beta-0.03 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Nigel James Theobald (Age 60)Founder, CEO & Executive Director Comp: $77.5kDr. David Templeton (Age 72)Executive Director & Technical Director Comp: $46.5kMr. Luke Sebastian Cairns (Age 46)Executive Director Comp: $41.33kRob HarrisHead of CMC DevelopmentDr. Andrew LeishmanConsultantKey CompetitorsHellenic DynamicsLON:HELDEvgen PharmaLON:EVGDeltex Medical GroupLON:DEMGPhysiomicsLON:PYCIntegrated DiagnosticsLON:IDHCView All Competitors N4P Stock Analysis - Frequently Asked Questions How have N4P shares performed in 2024? N4 Pharma's stock was trading at GBX 0.85 on January 1st, 2024. Since then, N4P shares have decreased by 5.9% and is now trading at GBX 0.80. View the best growth stocks for 2024 here. How were N4 Pharma's earnings last quarter? N4 Pharma Plc (LON:N4P) announced its quarterly earnings results on Thursday, September, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter. What other stocks do shareholders of N4 Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other N4 Pharma investors own include Intercede Group (IGP), Medpace (MEDP), Regeneron Pharmaceuticals (REGN), Sirius Minerals (SXX), SolGold (SOLG), Reach (RCH), Petra Diamonds (PDL), Interserve (IRV), Cornerstone Capital Resources (CGP) and Bushveld Minerals (BMN). How do I buy shares of N4 Pharma? Shares of N4P stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:N4P) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
